Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 199

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 199
---
 transactions contemplated by the SEPA; (vi) us having performed, satisfied, and complied in all material respects with all covenants, agreements, and conditions required by the SEPA to be performed, satisfied, or complied with by us; (vii) no statute, rule, regulation, executive order, decree, ruling, or injunction having been enacted, entered, promulgated, or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly, materially, and adversely affects any of the transactions contemplated by the SEPA; (viii) trading in the common shares have not been suspended by the SEC, the Nasdaq Capital Market or FINRA (ix) no notice having been provided to us that the listing or quotation of the common shares shall be terminated; (x) no continued suspensions or restrictions by DTC of, nor continued notices that DTC is contemplating or imposing suspensions or restrictions on, accepting deposits of the common shares, electronic trading or book-entry services by DTC with respect to the common shares; (xi) the common shares issuable pursuant to the applicable Advance Notice being eligible for deposit at the brokerage account provided by the Selling Shareholder for the delivery of such common shares; (xii) the common shares being duly authorized by all necessary corporate action of the company; and (xiii) all Advance Shares relating to all prior Advances having been delivered by us.

Termination of the SEPA

Unless earlier terminated as provided in the SEPA, the SEPA will terminate automatically on the earlier to occur of (i) the 36-month anniversary of the date of the SEPA and (ii) the date on which the Selling Shareholder shall have purchased common shares under the SEPA for an aggregate gross purchase price equal to $15,000,000.

We also have the right to terminate the SEPA at any time, at no cost or penalty, upon five trading days' prior written notice to the Selling Shareholder; provided that (i) there are no outstanding Advance Notices under which we are yet to issue common shares and (ii) we have paid all amounts owed to the Selling Shareholder pursuant to the SEPA. We and the Selling Shareholder may also terminate the SEPA at any time by mutual written consent.

No Short-Selling by the Selling Shareholder

The Selling Shareholder has agreed that neither it nor any of its officers, or any entity managed and controlled by the Investor will engage in any short sales during the term of the SEPA and will not enter into